The present invention is related to a combination of a steroid sulfatase inhibitor, E2MATE or EMATE, with norethindrone (NET) or norethindrone acetate (NETA) for use in the prevention or treatment of endometriosis. The present invention further relates to a method for preventing or treating endometriosis.

The present invention is related to a combination of a steroid sulfatase inhibitor, E2MATE or EMATE, with norethindrone (NET) or norethindrone acetate (NETA) for use in the prevention or treatment of endometriosis. The present invention further relates to a method for preventing or treating endometriosis.

PROBLEM TO BE SOLVED: To provide new pharmaceutical formulations containing surprisingly low concentrations of estradiol and norethindrone acetate (hereinafter designated NETA) to be used for the treatment of hormone placement therapy (HRT).

A method of contraception that provides for sequentially administering to a female of child bearing age: (a) a first composition containing a progestin in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 20 meg of ethinyl estradiol for about 22 to about 26 days

Methods for modulating hormonal pathways involving the progesterone receptor in a subject with a neurodegenerative disorder are provided. Progesterone receptor activity is modulated by administering an effective amount of an progesterone receptor modulating pharmacological agent to a subject such that the progesterone receptor modulating pharmacological agent interacts with the progesterone receptor and alters the expression of a protein associated with the neurodegenerative disease.